Ionis Pharmaceuticals
IONS
355 hedge funds and large institutions have $6.3B invested in Ionis Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 131 increasing their positions, 108 reducing their positions, and 52 closing their positions.
142% more capital inflows, than outflows
Capital inflows: $1.1B | Capital outflows: $457M
53% more call options, than puts
Call options by funds: $38M | Put options by funds: $24.8M
21% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 108
1.53% more ownership
Funds ownership: 98.16% → 99.69% (+1.5%)
2% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 52
1% less funds holding
Funds holding: 357 → 355 (-2)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$259M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$101M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$81.3M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$71.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$80.7M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$51.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$51.3M |
| 4 |
ClearBridge Investments
New York
|
-$21.3M |
| 5 |
Bellevue Group
Kuesnacht,
Switzerland
|
-$18M |
IONS Hedge Fund Activity: Q3 2024 in Review
355 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2024, worth a combined $6.3B — down 7.7% from $6.83B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new IONS positions and 52 closed out — a net gain of 1 holder — while 131 added to existing stakes and 108 trimmed.
The largest buyer was Capital World Investors, adding an estimated $259M. The largest seller was BVF Inc, cutting an estimated $80.7M.
- 355 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2024, down from 357 in Q2 2024.
- Funds reported $6.3B of Ionis Pharmaceuticals stock for Q3 2024, down 7.7% quarter-over-quarter.
- 53 funds opened new Ionis Pharmaceuticals positions in Q3 2024 and 52 closed out, a net change of +1 holder.
- The largest Ionis Pharmaceuticals buyer in Q3 2024 was Capital World Investors, an estimated $259M added.
- The largest Ionis Pharmaceuticals seller in Q3 2024 was BVF Inc, an estimated $80.7M sold.
Based on aggregated 13F filings for Q3 2024.